New: our quarterly report on the S&P 500, read from 500 companies’ own filings and calls. Read the Q3 2026 report

Radiopharm Theranostics Limited - Sponsored ADR

RADX

Healthcare Biotechnology

Radiopharm Theranostics Limited - Sponsored ADR’s revenue for fiscal 2026 (year ended June 2026) was $1.9 million, down 20.2% from fiscal 2025.

0.63 0.04 −5.97%

After hours trading: 0.60, down 4.76%, last trade Fri 4:27pm Eastern.

Market cap
$10.6M
P/E
—
Fwd P/E FY27e
—
Dividend yield
—
F-score
3/9
ROIC
—
Net debt / EBITDA
0.1×
Payout ratio
—
Jun '26 Dec '25 Jun '25 Dec '24 Older periods
Current Ratio
1.16 3.01 2.67 3.37

+1 more quarter

Debt/Equity
0.00 0.00 0.00 0.00
Free Cash Flow per Share
0.00 0.00 0.00 0.00
Free Cash Flow
(35.82) (14.88) (23.73) (14.47)
Other line items

Show all line items

Columns are period end dates · fundamentals updated Nov 2, 2026